1 / 12

The ACUITY Trial randomized 13,819 patients with moderate and high-risk NSTE-ACS.

Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial. Steven V. Manoukian, George D. Dangas, Michele D. Voeltz, Frederick Feit, Roxana Mehran, and Gregg W. Stone

hoshi
Download Presentation

The ACUITY Trial randomized 13,819 patients with moderate and high-risk NSTE-ACS.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian, George D. Dangas, Michele D. Voeltz, Frederick Feit, Roxana Mehran, and Gregg W. Stone Emory University School of Medicine, Atlanta, GA; Columbia University Medical Center and The Cardiovascular Research Foundation, New York, NY; New York University School of Medicine, New York, NY

  2. UFH or Enoxaparin + GP IIb/IIIa Bivalirudin + GP IIb/IIIa Angiography within 72h R* Bivalirudin Alone STUDY DESIGN • The ACUITY Trial randomized 13,819 patients with moderate and high-risk NSTE-ACS. Medical management Moderate- high risk ACS PCI Aspirin in all Clopidogrel dosing and timing per local practice CABG

  3. PNI <0.001 PSup = 0.015 PNI <0.001 PSup <0.001 PNI = 0.011 PSup = 0.32 ACUITY Primary Results – 30 Days

  4. ACUITY Primary Results – 1 Year

  5. BACKGROUND & OBJECTIVES • Baseline anemia is associated with an increased risk of short-term (30-day) ischemic complications and mortality in ACS. Whether anemia adversely impacts long-term outcomes is less clear. • Anemia was defined using WHO criteria: - hgb <13 g/dL men - hgb <12 g/dL women • We assessed the impact of anemia on rates of long-term (1-year) ischemic events and mortality in patients with ACS in the ACUITY trial.

  6. Baseline Characteristics

  7. P=<0.0001 P=<0.0001 P=<0.0001 Anemic vs Non-Anemic Population 30-Day Event Rates

  8. Anemic vs Non-Anemic Population: 1-Year Ischemic Event Rates P<0.0001

  9. P=0.74 P=0.59 P=0.71 P=0.77 P=0.81 P=0.052 Anemic Population 30-Day Event Rates by Treatment

  10. Anemic vs Non-Anemic Population: 1-Year Mortality P<0.0001

  11. Baseline Independent Predictors of 1-Year Mortality HR ±95% CI HR (95% CI)

  12. CONCLUSIONS • Anemia is not uncommon in patients with ACS (16.9%). • Anemia is associated with a significant increase in rates of long-term (1-year) ischemic events. • Anemia is associated with an over 2-fold increase in rates of long-term (1-year) mortality and is an independent predictor of long-term (1-year) mortality in patients with ACS.

More Related